跳转至内容
Merck
所有图片(1)

文件

CDS023093

Sigma-Aldrich

尼洛替尼

别名:

4-甲基-3-[[4-(3-吡啶)-2-嘧啶]氨基]-N-[5-(4-甲基-1H-咪唑-1-基)-3-(三氟甲基)苯基]苯甲酰胺, 4-甲基-N-[3-(4-甲基-1H-咪唑-1-基)-5-(三氟甲基)苯基]-3-[[4-(3-吡啶)-2-嘧啶]氨基]苯甲酰胺, 4-甲基-N-[3-(4-甲基咪唑-1-基)-5-三氟甲基苯基]-3-[[4-(吡啶-3-基)嘧啶-2-基]氨基]苯甲酰胺

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C28H22F3N7O
CAS号:
641571-10-0
分子量:
529.52
MDL號碼:
MFCD09833716
分類程式碼代碼:
12352200
PubChem物質ID:
329796354

描述

AldrichCPR

形狀

solid

儲存溫度

-10 to -25°C

SMILES 字串

CC1=CN(C2=CC(NC(C3=CC=C(C(NC4=NC=CC(C5=CC=CN=C5)=N4)=C3)C)=O)=CC(C(F)(F)F)=C2)C=N1

InChI

1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)

InChI 密鑰

HHZIURLSWUIHRB-UHFFFAOYSA-N

基因資訊

human ... ABL1(25)

一般說明

尼洛替尼(Nilotinib)是氨基嘧啶类衍生物，可用作酪氨酸激酶受体的选择性抑制剂。也可作为抗肿瘤和抗冠状病毒药物。

其他說明

请注意，Sigma-Aldrich将此产品作为一系列独特化学品的一部分提供给早期发现研究人员。Sigma-Aldrich不会收集该产品的分析数据。买方需承担确认产品标识和/或纯度的责任。所有销售均为最终销售。

尽管SIGMA-ALDRICH的标准条款和条件以及SIGMA-ALDRICH′S和买方之间的协议中包含所有合同条款，但无论是在法律、交易过程、执行过程中的行为、以及贸易或其他方面的使用等过程中，SIGMA-ALDRICH按“原样”销售此产品并且并对此产品不作任何陈述或担保，包括：（A）适销性担保；（B）特定用途适用性担保；或（C）未侵犯第三方知识产权担保。

象形圖

Health hazard
GHS08

訊號詞

Danger

危險聲明

H372,H413

危險分類

Aquatic Chronic 4 - STOT RE 1

標靶器官

Liver,Kidney,gallbladder

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類（WGK）

WGK 2

閃點（°F）

Not applicable

閃點（°C）

Not applicable

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

A Hochhaus et al.
Leukemia, 31(7), 1525-1531 (2017-02-22)
The single-arm, phase 2 ENESTfreedom trial assessed the potential for treatment-free remission (TFR; i.e., the ability to maintain a molecular response after stopping therapy) following frontline nilotinib treatment. Patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase with MR
Fabienne Lamballe et al.
Oncotarget, 7(46), 74747-74767 (2016-10-13)
The cytoplasmic tyrosine kinase ABL exerts positive or negative effects in solid tumours according to the cellular context, thus functioning as a "switch modulator". The therapeutic effects of drugs targeting a set of signals encompassing ABL have been explored in
Hans Gelderblom et al.
The Lancet. Oncology, 19(5), 639-648 (2018-03-25)
Pigmented villonodular synovitis (alternatively known as diffuse-type giant cell tumour) is a rare, locally aggressive tumour driven by a specific translocation resulting in the overexpression of colony-stimulating factor 1 (CSF1). CSF1 receptor (CSF1R) inhibitors (ie, tyrosine kinase inhibitors and antibodies)
Konstantin Byrgazov et al.
Oncotarget, 7(47), 78083-78094 (2016-11-02)
Point mutations in the ABL1 kinase domain are an important mechanism of resistance to tyrosine kinase inhibitors (TKI) in BCR-ABL1-positive and, as recently shown, BCR-ABL1-like leukemias. The cell line Ba/F3 lentivirally transduced with mutant BCR-ABL1 constructs is widely used for
Hélène Bon et al.
Nephron, 142(4), 328-350 (2019-05-03)
Tubulointerstitial fibrosis is a key feature of chronic kidney diseases leading to renal failure. It is characterised by the infiltration of fibroblasts and aberrant accumulation of extracellular matrix (ECM) proteins, which are associated with progressive loss of renal function. Integrins
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门